Equinor to commence fourth and final tranche of the 2023 share buy-back programme
Equinor (OSE: EQNR, NYSE: EQNR) will on 30 October 2023 commence the fourth tranche of the share buy-back programme for 2023 of up to USD 1.67 billion, as announced in relation with the third quarter results on 27 October 2023. The fourth tranche will end no later than 29 January 2024.
The purpose of the share buy-back programme is to reduce the issued share capital of the company. All shares repurchased as part of the programme will hence be cancelled.
According to an agreement between Equinor and the Norwegian State, a proportionate number of the Norwegian State’s shares shall be redeemed and cancelled at the annual general meeting in 2024, ensuring that the State’s ownership interest in Equinor remains unchanged at 67%.
The share buy-back programme for 2023 is structured into tranches where Equinor will buy back shares for a certain value in USD over a defined period. For the fourth tranche of 2023, Equinor is entering into a non-discretionary agreement with an independent third party who will execute repurchases of shares and make its trading decisions independently of the company.
In this fourth tranche, shares for up to USD 550 million will be purchased in the market, implying a total fourth tranche of up to USD 1.67 billion, including shares to be redeemed from the Norwegian State.
This fourth and final tranche will complete Equinor’s announced share buy-back programme of USD 6 billion for 2023.
Further information about the share buy-back programme and the fourth tranche:
The fourth tranche of the share buy-back programme for 2023 is based on an authorisation granted to the Board of Directors at the annual general meeting 10 May 2023. According to the authorisation, the maximum number of shares which can be purchased in the market is 94,000,000 of which 57,290,207 remain available per commencement of the fourth tranche (taken into account buy-backs made under previous tranches). The minimum price that can be paid per share pursuant to the authorisation is NOK 50 and the maximum price is NOK 1,000. The authorisation is valid until the earliest of 30 June 2024 and the annual general meeting in 2024.
An agreement between Equinor and the Norwegian State regulates the State’s participation in the share buy-back: At the annual general meeting in 2024, the State will, as per proposal by the Board of Directors, vote for the cancellation of shares purchased in the market pursuant to the board authorisation, and the redemption and cancellation of a proportionate number of its shares in order to maintain its ownership share in the company. The price to be paid to the State for redemption of the State’s shares shall be the volume-weighted average of the price paid by Equinor for shares purchased in the market plus an interest rate compensation, adjusted for any dividends paid.
In the fourth tranche in 2023, shares will be purchased on the Oslo Stock Exchange and possibly other trading venues within the EEA. Transactions will be conducted in accordance with applicable safe harbour conditions, and as further set out i.a. in the Norwegian Securities Trading Act of 2007, EU Commission Regulation (EC) No 2016/1052 and the Oslo Stock Exchange's Guidelines for buy-back programmes and price stabilization from February 2021.
Based on the above and similar to the second and third tranche of Equinor’s share buy-back programme, the Board of Directors will propose to the annual general meeting in 2024 to cancel shares purchased in this fourth tranche and redeem a proportionate number of the State’s shares.
This is information that Equinor is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Further information from:
Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+ 47 918 01 791
Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Omkostningsreduktion på DKK ca. 45 mio.28.11.2023 13:32:23 CET | pressemeddelelse
Selskabsmeddelelse nr. 37/2023 Holbæk, den 28. november 2023 Omkostningsreduktion på DKK ca. 45 mio. Sparekassen Sjælland Fyn A/S har i dag gennemført en reduktion af medarbejderstaben med 29 (5 % af medarbejderstaben). 21 medarbejdere er fratrådt i dag, de øvrige 8 medarbejdere er kommende pensioneringer og stillingsbortfald. Herudover er der en række øvrige driftsomkostninger, som det er lykkedes at eliminere. Samlet set bremses de årlige omkostninger med DKK ca. 45 mio. (ca. 5 %) med fuld effekt fra 1. januar 2024. ”De gennemførte medarbejder- og omkostningsreduktioner er udtryk for, at sparekassen hele tiden arbejder med at trimme forholdet mellem indtægter og omkostninger ” udtaler adm. direktør Lars Petersson. ”Virkeligheden er, at aktivitetsniveauet – særligt på boligområdet – er langt lavere end de senere år. Herudover har vi hurtigere end forventet eksekveret på en lang række teknologiske effektiviseringer jf. vores strategi. Det betyder, at vi kan drive sparekassen mere effek
Changes in the number of own shares held by Aktia Bank Plc28.11.2023 13:00:00 CET | Press release
Aktia Bank Plc Stock Exchange Release 28 November 2023 at 2.00 p.m. Changes in the number of own shares held by Aktia Bank Plc Aktia Bank Plc has today, based on a decision made by the company's Board of Directors, divested a total of 808 own shares held by the company to four persons as a deferred payment based on the company’s remuneration programs. The divestment of own shares is based on the authorisation by the Annual General Meeting of Shareholders held on 5 April 2023. After the above-mentioned divestments, a total of 159,538 shares remain in the company’s possession. Aktia Bank Plc Further information: Mia Smeds, Communications director, +358 44 546 0379, mia.smeds(at)aktia.fi Distribution: Nasdaq Helsinki Ltd Mass media www.aktia.com Aktia is a Finnish asset manager, bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in the Helsink
Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning28.11.2023 13:00:00 CET | Pressemelding
Aktia Bank Abp Börsmeddelande 28.11.2023 kl. 14.00 Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning Aktia Bank Abp har idag med stöd av ett beslut av bolagets styrelse överlåtit totalt 808 Aktia-aktier i bolagets besittning till fyra personer som betalning av uppskjutna ersättningar enligt bolagets belöningssystem. Överlåtelsen av aktier är baserad på bemyndiganden av den ordinarie bolagsstämman 5.4.2023. Efter ovan nämnda överlåtelser har bolaget sammanlagt 159 538 aktier i sin besittning. Aktia Bank Abp Mera information: Mia Smeds, kommunikationsdirektör, tfn 044 546 0379, mia.smeds(at)aktia.fi Distribution: Nasdaq Helsinki Oy Massmedier www.aktia.com Aktia är en finländsk kapitalförvaltare, bank och livförsäkrare som har skapat välstånd och välfärd generation efter generation redan under 200 års tid. Vi tillhandahåller våra kunder digitala tjänster i ett flertal kanaler och ger personlig service på våra verksamhetsställen i huvudstadsregionen samt i Åbo-, Tammerfors-, V
Karolinska Developments portföljbolag Umecrine Cognition presenterar positiv effekt med golexanolon i en preklinisk modell av kolestas28.11.2023 12:44:51 CET | Pressemelding
STOCKHOLM, SVERIGE 28 november 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har presenterat positiva resultat från en studie med bolagets läkemedelskandidat golexanolone i en preklinisk modell av PBC-relaterad symtomologi och neuroinflammation. Resultaten indikerar en normaliserande effekt på kognitiva symtom såsom trötthet, motoriska störningar, neuroinflammation och neurala signaler. Resultaten publiceras i novemberutgåvan av den internationellt välrenommerade tidskriften Liver International. Resultaten från den prekliniska studien, som utfördes i en validerad och välkänd sjukdomsmodell av kolestas, visar att golexanolon förbättrar symtom som vanligtvis ses vid PBC. Studien visar en tydlig minskning av central trötthet, signifikanta förbättringar av korttidsminnet och normaliserande motoriska funktioner efter en 4-5 veckors lång behandling med golexanolon. ”Trötthet är högst prioriterat för symtomlindring för PBC-patienter e
Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis28.11.2023 12:44:51 CET | Press release
STOCKHOLM, SWEDEN – November 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented positive results from a study of the company’s drug candidate golexanolone in a preclinical model of PBC-like symptomology and neuroinflammation. The results indicate a normalizing effect on cognitive symptoms, such as fatigue, motor impairments, neuroinflammation, and neural signaling. The results are published in the November issue of the internationally renowned journal Liver International. The results from the preclinical study, which was performed in a validated and well-known disease model of cholestasis, show that golexanolone improves symptoms generally seen in PBC. The study shows a clear reduction in central fatigue, marked improvements in short-term memory, and normalized motoric functions following a 4–5-week treatment regimen with golexanolone. “Fatigue is the highest priority of symptom relief for PBC patient